Mikhail Blagosklonny’s Research on Aging and Cancer Treatment

Mikhail  is a philanthropist and an Oncology professor at Rosewell Park Cancer in Buffalo, New York. He has conducted a lot of research on cancer and its remedies. He is also Editor-in-Chief of Oncotarget where he has conducted research and published many articles on the subject of aging. Mikhail Blagosklonny has recommended the use of the cancer drug Rapamycin for the intention of increasing human’s lifespan. Rapamycin is also known as Sirolimus. This is a drug used to prevent the body from rejecting an organ transplant. It is also a cancer drug and has been used as a coronary stent coating and treating rare lung diseases. In the pharmacy market, its trade name is Rapamune. The drug was first used as an antifungal agent, and later it was discovered to have antiproliferative and immunosuppressive characteristics.

Rapamycin has less toxic effects on kidneys compared to other immunosuppressive drugs or calcineurin inhibitors which have an adverse impact on the kidney over an extended period of time. Rapamycin is, therefore, the best option as an anti-rejection drug. The use of this drug also protects a newly transplanted liver from contacting hemolytic-uremic syndrome, an unusual disease caused by the failure of kidney, anemia and low platelet count leading to renal failure. This drug has also been found to cure Lymphangioleiomyomatosis (LAM) a rare lung disease usually affecting women of childbearing age. Research has shown that when Rapamycin is used in a coronary stent coating, there are lower rates of reoccurrence of re-stenosis thus one does not repeat the procedure often. This drug is known to suppress tumors, and when taken in the right dosage it can enhance immunity system towards the tumor growth in cancer patients.

Dr. Mikhail Blagosklonny has conducted research on the ability of this drug to rejuvenate the immunity system, especially in aging patients. He has played a major role in pioneering the use of this drug in treatment and prevention of many diseases as well as increasing the human lifespan through stopping the genes responsible for the aging process. By delaying the aging process, it also delays the onset of age-related diseases. More research about the drug is still going on.

As a philanthropist, Dr. Mikhail is working towards making sure that people have the best treatment possible all around the world. His research is mostly focused on the study of aging as well as cancer and the relationship between the two. He is in particular engrossed in why cancer is most common amongst people above a certain age. His research focuses on treating cancer efficiently and less expensively compared to today’s cancer treatments. He wants to find a way to get rid of cancer cells without affecting the cells responsible for the recovering of mind and body tissues and memory. He believes that in future cancer treatment will be readily available to everyone and hopes that other doctors will be inspired by his work and continue his research after him. He also optimistic that the research he is conducting will continue to be useful in the oncology field